20:13 EDT Cathie Wood’s ARK Investment buys 181.3K shares of Crispr Therapeutics (CRSP) today
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRSP:
- Crispr Therapeutics AG: Strong Financial Foundation and Promising Pipeline Amidst Strategic Growth
- Crispr Therapeutics AG: Promising Growth and Expanding Pipeline Justify Buy Rating
- CRISPR Therapeutics Reports Q2 2025 Progress and Financials
- Cautious Hold Rating for Casgevy Amid Growth and Upcoming Data Releases
- Closing Bell Movers: Palantir hits record highs on beat and raise